MabVax Raises $5.25M
San Diego-based MabVax Therapeutics, a developer of immunotherapies aimed at preventing recurrent cancer, said today that it has raised $5.25M in a funding round. The round was led by Numoda Capital Innovation, and also included Burrill Capital Fund IV and RTP Venture Fund. MabVax said the funding will go towards its phase 2 vaccine aimed at preventing recurrent sarcoma, as well as an antibody program targeting metastatic pancreatic cancer.
posted on Tuesday, November 20, 2012 (Link to more information)

Related companies:
Mabvax Therapeutics

Related stories:
> MabVax Raises $3M, Completes Merger With Telik
> MabVax Therapeutics Raises $8M For Cancer Treatment
> MabVax Therapeutics Raises $4.1M In PIPE
> MabVax Raises $9.4M In PIPE
> Mabvax Finds $500K Home